PDCD1 and cancer: The results showed that combination therapy of chemotherapy plus sintilimab (anti‐PD1) was associated with statistically significant improvements in PFS (HR = 0.12, 95% CI: 0.06–0.25, p < 0.001) and OS (HR = 0.27, 95% CI: 0.13–0.55, p < 0.001) only for subtype II (PDL1+ and TIL+) compared with chemotherapy, which further illustrates the critical role of immune cells in cancer immunotherapy.233